Skip to content

NYSE · CIK 0001724521

RCUS Arcus Biosciences, Inc.

Insider trading from SEC Form 4. Last filing Sep 30, 2025. Close $24.41 on Oct 9, 2026, +67% from the 52-week low and -23% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
16
with a Form 4 at this company

Price and insider trades, last year

RCUSOct 9, 2026 · close 24.41

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Arcus Biosciences, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
1WeakAlexander Azoy
Chief Accounting Officer
sell
$37k
2,831 shares
-9%+94% from low-28% from high
0WeakAlexander Azoy
Chief Accounting Officer
sell
$19k
1,579 shares
-5%+77% from low-34% from high
47ModerateTerry J Rosen
Chief Executive Officer
buy
$201k
19,800 shares
+1%-
52ModerateYasunori Kaneko
director
buy
$201k
20,000 shares
+238%-
47ModerateGilead Sciences, Inc.
owner
buy
$15M
1,363,636 shares
+5%-
9WeakRobert C. Goeltz II
Chief Financial Officer
sell
$54k
3,594 shares
-6%-
0WeakAlexander Azoy
Chief Accounting Officer
sell
$3,079
201 shares
-1%-

Transactions

The last 45 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 29, 2025Alexander Azoy
Chief Accounting Officer
SOpen-market sale
Common Stock10b5-1
-2,831$13.00$37k27,363Sep 30, 2025
Sep 5, 2025Alexander Azoy
Chief Accounting Officer
SOpen-market sale
Common Stock10b5-1
-1,579$11.88$19k30,194Sep 5, 2025
Jun 10, 2025Nicole Lambert
director
AGrant or award
Common Stock
+13,300$0.00$037,300Jun 12, 2025
Jun 10, 2025Yasunori Kaneko
director
AGrant or award
Common Stock
+13,300$0.00$033,300Jun 12, 2025
Jun 10, 2025David L. Lacey
director
AGrant or award
Common Stock
+13,300$0.00$070,952Jun 12, 2025
Jun 10, 2025Antoni Ribas
director
AGrant or award
Common Stock
+13,300$0.00$043,650Jun 12, 2025
Jun 10, 2025Patrick Machado
director
AGrant or award
Common Stock
+13,300$0.00$038,600Jun 12, 2025
Jun 10, 2025Kathryn E Falberg
director
AGrant or award
Common Stock
+13,300$0.00$068,600Jun 12, 2025
Jun 10, 2025Andrew J Perlman
director
AGrant or award
Common Stock
+13,300$0.00$042,625Jun 12, 2025
Jun 10, 2025Nicole Lambert
director
AGrant or award
Stock Option (Right to Buy)derivative
+38,300$0.00$038,300Jun 12, 2025
Jun 10, 2025David L. Lacey
director
AGrant or award
Stock Option (Right to Buy)derivative
+38,300$0.00$038,300Jun 12, 2025
Jun 10, 2025Patrick Machado
director
AGrant or award
Stock Option (Right to Buy)derivative
+38,300$0.00$038,300Jun 12, 2025
Jun 10, 2025Andrew J Perlman
director
AGrant or award
Stock Option (Right to Buy)derivative
+38,300$0.00$038,300Jun 12, 2025
Jun 10, 2025Antoni Ribas
director
AGrant or award
Stock Option (Right to Buy)derivative
+38,300$0.00$038,300Jun 12, 2025
Jun 10, 2025Kathryn E Falberg
director
AGrant or award
Stock Option (Rights to Buy)derivative
+38,300$0.00$038,300Jun 12, 2025
Jun 10, 2025Yasunori Kaneko
director
AGrant or award
Stock Option (Right to Buy)derivative
+38,300$0.00$038,300Jun 12, 2025
Feb 27, 2025Yasunori Kaneko
director
POpen-market purchase
Common Stock
+20,000$10.06$201k28,400Feb 27, 2025
Feb 27, 2025Terry J Rosen
Chief Executive Officer
POpen-market purchase
Common Stock
+19,800$10.18$201k2,554,160Feb 27, 2025
Feb 18, 2025Gilead Sciences, Inc.
owner
POpen-market purchase
Common Stock
+1,363,636$11.00$15M31,424,760Feb 20, 2025
Feb 10, 2025Richard Markus
Chief Medical Officer
AGrant or award
Common Stock
+75,193$0.00$075,193Feb 11, 2025
Feb 10, 2025Richard Markus
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative
+305,328$0.00$0305,328Feb 11, 2025
Jan 23, 2025Carolyn C. Tang
General Counsel
AGrant or award
Common Stock
+37,000$0.00$0137,623Jan 27, 2025
Jan 23, 2025Terry J Rosen
Chief Executive Officer
AGrant or award
Common Stock
+165,000$0.00$02,534,360Jan 27, 2025
Jan 23, 2025Jennifer Jarrett
Chief Operating Officer
AGrant or award
Common Stock
+50,000$0.00$0213,369Jan 27, 2025
Jan 23, 2025Robert C. Goeltz II
Chief Financial Officer
AGrant or award
Common Stock
+37,000$0.00$097,138Jan 27, 2025
Jan 23, 2025Alexander Azoy
Chief Accounting Officer
AGrant or award
Common Stock
+17,100$0.00$030,194Jan 27, 2025
Jan 23, 2025Juan C. Jaen
President
AGrant or award
Common Stock
+50,000$0.00$0367,220Jan 27, 2025
Jan 23, 2025Alexander Azoy
Chief Accounting Officer
AGrant or award
Stock Option (right to buy)derivative
+11,400$0.00$011,400Jan 27, 2025
Jan 23, 2025Robert C. Goeltz II
Chief Financial Officer
AGrant or award
Stock Option (right to buy)derivative
+150,000$0.00$0150,000Jan 27, 2025
Jan 23, 2025David L. Lacey
director
AGrant or award
Stock Option (right to buy)derivative
+5,000$0.00$05,000Jan 27, 2025
Jan 23, 2025Jennifer Jarrett
Chief Operating Officer
AGrant or award
Stock Option (right to buy)derivative
+200,000$0.00$0200,000Jan 27, 2025
Jan 23, 2025Carolyn C. Tang
General Counsel
AGrant or award
Stock Option (right to buy)derivative
+150,000$0.00$0150,000Jan 27, 2025
Jan 23, 2025Terry J Rosen
Chief Executive Officer
AGrant or award
Stock Option (right to buy)derivative
+650,000$0.00$0650,000Jan 27, 2025
Jan 23, 2025Juan C. Jaen
President
AGrant or award
Stock Option (right to buy)derivative
+200,000$0.00$0200,000Jan 27, 2025
Jan 23, 2025Antoni Ribas
director
AGrant or award
Stock Option (right to buy)derivative
+5,000$0.00$05,000Jan 27, 2025
Dec 31, 2024Robert C. Goeltz II
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-3,594$15.00$54k60,138Jan 3, 2025
Dec 19, 2024Alexander Azoy
Chief Accounting Officer
DDisposition to issuer
Common Stock10b5-1
-3,007$15.17$46k13,094Dec 20, 2024
Dec 15, 2024Juan C. Jaen
President
FTax withholding
Common Stock
-17,286$16.08$278k317,220Dec 17, 2024
Dec 15, 2024Alexander Azoy
Chief Accounting Officer
FTax withholding
Common Stock
-2,969$16.08$48k16,101Dec 17, 2024
Dec 15, 2024Robert C. Goeltz II
Chief Financial Officer
FTax withholding
Common Stock
-10,099$16.08$162k63,732Dec 17, 2024
Dec 15, 2024Nuyten Dimitry SA
Chief Medical Officer
FTax withholding
Common Stock
-7,856$16.08$126k87,518Dec 17, 2024
Dec 15, 2024Terry J Rosen
Chief Executive Officer
FTax withholding
Common Stock
-37,882$16.08$609k2,369,360Dec 17, 2024
Dec 15, 2024Carolyn C. Tang
General Counsel
FTax withholding
Common Stock
-11,339$16.08$182k100,623Dec 17, 2024
Dec 15, 2024Jennifer Jarrett
Chief Operating Officer
FTax withholding
Common Stock
-27,501$16.08$442k163,369Dec 17, 2024
Dec 2, 2024Alexander Azoy
Chief Accounting Officer
SOpen-market sale
Common Stock10b5-1
-201$15.32$3,07919,070Dec 4, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

RCUS insider trading: Arcus Biosciences, Inc. | InsiderTell